The Directorate General of Health Services has invited comments on the use of brand name extensions in pharma, potentially signaling regulatory changes that could affect marketing strategies of pharmaceutical companies.
Regulatory Scrutiny of Pharma Brand Name Extensions
On July 6, 2026, the Directorate General of Health Services, part of the Central Drugs Standard Control Organization (CDSCO), issued a notice inviting public comments regarding the use of brand name extensions by pharmaceutical companies. This development could indicate a significant regulatory shift in the marketing practices of the pharma sector.
The scrutiny comes in response to longstanding concerns which suggest that companies have been leveraging brand name extensions to sell different formulations under a singular brand identity, which could lead to consumer confusion and implications for drug safety. This move is underscored by representation made to the Drugs Consultative Committee indicating the need for clarity on this issue.
Industry experts Prashant and Dinesh Thakur emphasize that effective regulation in this area is crucial to ensure transparency and protect consumer interests. They advocate for stricter guidelines on how brand extensions may be used, highlighting the potential for misleading practices in pharmaceutical advertisement.
For legal practitioners in the pharmaceutical sector, this consultation represents an important opportunity to engage with regulators, as changes in these guidelines could impact the strategies of marketing and brand management within the industry moving forward.
